The first and only FDA-approved treatment for PH-ILD1
TYVASO SHIFTS
THE OUTLOOK FOR PH-ILD1
TYVASO and TYVASO DPI are inhaled prostacyclin mimetics indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.1,2
The study with TYVASO establishing effectiveness predominately included patients with etiologies of1,2:
- Idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF)
- Combined pulmonary fibrosis and emphysema (CPFE) (25%)
- WHO Group 3 connective tissue disease (22%)
Eligible patients
could pay as little
as a $0 co-pay
for each prescription
Learn about support
services for patients
Get in contact with a United Therapeutics Representative
The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.